216 results on '"Yuda, Junichiro"'
Search Results
2. Current status of BAFF targeting immunotherapy in B-cell neoplasm
3. Bridging horizons beyond CIRCULATE-Japan: a new paradigm in molecular residual disease detection via whole genome sequencing-based circulating tumor DNA assay
4. Valemetostat monotherapy in patients with relapsed or refractory non-Hodgkin lymphoma: a first-in-human, multicentre, open-label, single-arm, phase 1 study
5. Selective MCL-1 inhibitor ABBV-467 is efficacious in tumor models but is associated with cardiac troponin increases in patients
6. Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemia
7. Incidence of refractory cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation
8. Combination therapy with low doses of ponatinib and steroids in elderly and frail patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
9. Cytomegalovirus reactivation in patients with multiple myeloma administered daratumumab-combination regimens
10. First-in-human clinical trial results with ABBV-184, a first-in-class T-cell receptor/anti-CD3 bispecific protein, in adults with previously treated AML or NSCLC.
11. The critical role of CD4+ T cells in PD-1 blockade against MHC-II–expressing tumors such as classic Hodgkin lymphoma
12. Richter transformation acquiring PLCG2 mutation during Bruton tyrosine kinase inhibitors treatment
13. Molecular remission after combination therapy with blinatumomab and ponatinib with relapsed/refractory Philadelphia chromosome-positive acute lymphocytic leukemia: two case reports
14. Impact of TKI Switching, Reduction, and Discontinuation on Cardiovascular Events in cml patients
15. Subcutaneous epcoritamab monotherapy in Japanese adults with relapsed/refractory diffuse large B‐cell lymphoma
16. MO50-3 Preliminary data from the phase I/II study of TP-3654, an oral PIM-1 kinase inhibitor, in patients with myelofibrosis
17. O13-3 Subcutaneous epcoritamab in Japanese patients with relapsed/refractory diffuse large B-cell lymphoma: EPCORE NHL-3 data
18. P38-8 Phase 1/2 study of menin inhibitor DSP-5336 in acute leukemia with and without MLL rearrangement or NPM1 mutation
19. MPN-439 Preliminary Data From the Phase 1/2 Study of TP-3654, an Investigational Selective PIM1 Kinase Inhibitor, Showed Cytokine Reduction and Clinical Responses in Relapsed/Refractory Myelofibrosis (MF)
20. POSTER: MPN-439 Preliminary Data From the Phase 1/2 Study of TP-3654, an Investigational Selective PIM1 Kinase Inhibitor, Showed Cytokine Reduction and Clinical Responses in Relapsed/Refractory Myelofibrosis (MF)
21. Chronic myeloid leukemia stem cells and molecular target therapies for overcoming resistance and disease persistence
22. P1031: PRELIMINARY DATA FROM THE PHASE 1/2 STUDY OF TP-3654, AN INVESTIGATIONAL SELECTIVE PIM1 KINASE INHIBITOR, SHOWED CYTOKINE REDUCTION AND CLINICAL RESPONSES IN RELAPSED/REFRACTORY MYELOFIBROSIS
23. A TIM-3/Gal-9 Autocrine Stimulatory Loop Drives Self-Renewal of Human Myeloid Leukemia Stem Cells and Leukemic Progression
24. The ordered acquisition of Class II and Class I mutations directs formation of human t(8;21) acute myelogenous leukemia stem cell
25. Preliminary Data from the Phase I/II Study of TP-3654, a Selective Oral PIM1 Kinase Inhibitor, in Patients with Myelofibrosis Previously Treated with or Ineligible for JAK Inhibitor Therapy
26. Phase 1/2, Open-Label, Dose Escalation, Dose Expansion Study of Menin Inhibitor DSP-5336 in Adult Patients with Acute Leukemia with and without Mixed-Lineage Leukemia (MLL)-Rearrangement (R) or Nucleophosmin 1 (NPM1) Mutation (m)
27. A Practice-Oriented Genome Profiling Study with the Novel Halo-Shape Annealing and Defer-Ligation Enrichment (HANDLE) System : HM-Screen-JAPAN02
28. BATF epigenetically and transcriptionally controls the activation program of regulatory T cells in human tumors
29. Asciminib vs bosutinib in CML patients pretreated with ≥2 tyrosine kinase inhibitors: Results from the Japanese subgroup analysis of ASCEMBL study
30. TCL-391 Valemetostat Monotherapy in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas: Primary Results From a Phase 1 Trial
31. Valemetostat Monotherapy in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas: Primary Results From a Phase 1 Trial
32. MO10-2 Emerging molecular targets in AML: IDH1/2- and menin-related mutations (HM-SCREEN-JAPAN01)
33. Abstract 5185: First in human trial of off-the shelf iPS derived anti-GPC3 NK cells for recurrent ovarian clear cell carcinoma with peritoneal dissemination
34. Molecular Classification and Overcoming Therapy Resistance for Acute Myeloid Leukemia with Adverse Genetic Factors
35. Asciminib vs bosutinib in CML patients pretreated with ≥2 tyrosine kinase inhibitors: Results from the Japanese subgroup analysis of ASCEMBL study.
36. Hematologic Malignancies (HM)-Screen-Japan 01: A Mutation Profiling Multicenter Study on Patients with Acute Myeloid Leukemia
37. Properties and Distribution of IDH-1/2 Mutations in Acute Myeloid Leukemia By the Comprehensive Genomic Analysis
38. Genomic Analysis Focusing on RUNX1-RUNX1T1 in Japanese Patients with AML: HM-Screen-Japan 01
39. Genomic Analysis of NPM1 Mutation and KMT2A(MLL)-Rearrangement/Amplification in Japanese Patients with Acute Myeloid Leukemia: Hematologic Malignancies (HM)-Screen-Japan 01
40. Clinical Significance of FLT3 Mutations in a Comprehensive NGS Multicenter Study of AML: HM-Screen-Japan 01
41. Incidence of refractory cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation
42. A Phase 1 Study of PIT565, a First-in-Class, Anti-CD3, Anti-CD19, Anti-CD2 Trispecific Antibody in Patients with Relapsed and/or Refractory B-Cell Malignancies
43. Phase 1/2 First-in-Human Study of the Menin-MLL Inhibitor DSP-5336 in Patients with Relapsed or Refractory Acute Leukemia
44. Mechanism of Late Recurrences of Chronic Myeloid Leukemia after Discontinuation of TKI Therapy: BCR::ABL1 Ins35bp Loss-of-Function Splicing Mutation and Regulatory T Cells
45. Phase 1/2 Study of TP-3654, a Selective PIM1 Kinase Inhibitor: Preliminary Data Showed Clinical Activity and Cytokine Reductions in Relapsed/Refractory Myelofibrosis Patients
46. Phase 1 first-in-human study of ABBV-184 monotherapy in adult patients with previously treated acute myeloid leukemia or non-small cell lung cancer.
47. Brentuximab vedotin maintenance after autologous stem cell transplantation for refractory gray zone lymphoma with long‑term remission
48. Cytomegalovirus reactivation in patients with multiple myeloma administered daratumumab-combination regimens
49. Emerging Immunotherapy for Acute Myeloid Leukemia
50. STAMP inhibitor Asciminib and medium-chain fatty-acid derivative AIC-47: novel therapies for chronic myeloid leukemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.